Common Stock Valuation Ratios (Price Multiples)
Quarterly Data
Valuation ratios measure the quantity of an asset or flaw (e.g., earnings) associated with ownership of a specified claim (e.g., a share of ownership of the enterprise).
Historical Valuation Ratios (Summary)
AmerisourceBergen Corp., historical price multiples (quarterly data)
Based on: 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-Q (reporting date: 2022-12-31), 10-K (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-K (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-K (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-K (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-K (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-K (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-Q (reporting date: 2016-12-31).
| Valuation ratio | Description | The company |
|---|---|---|
| P/E ratio | The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. | AmerisourceBergen Corp. P/E ratio increased from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023. |
| P/OP ratio | Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. | AmerisourceBergen Corp. P/OP ratio increased from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023. |
| P/S ratio | An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. | AmerisourceBergen Corp. P/S ratio increased from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023. |
Price to Earnings (P/E)
AmerisourceBergen Corp., historical P/E calculation (quarterly data)
| Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 202,174,856 | 202,466,004 | 202,258,188 | 205,668,628 | 207,258,092 | 209,464,050 | 209,137,429 | 208,133,361 | 207,787,116 | 205,410,717 | 204,706,150 | 204,249,747 | 204,141,795 | 203,402,770 | 205,891,754 | 205,922,186 | 208,325,501 | 210,176,951 | 211,089,893 | 211,933,493 | 216,356,644 | 219,804,069 | 219,669,091 | 218,082,051 | 219,111,565 | 218,356,117 | 217,279,686 | ||||||||
| Selected Financial Data (US$) | |||||||||||||||||||||||||||||||||||
| Net income (loss) attributable to AmerisourceBergen Corporation (in thousands) | 479,581) | 435,402) | 479,745) | 294,737) | 406,964) | 548,014) | 449,105) | 437,698) | 292,122) | 435,267) | 374,845) | (4,846,072) | 289,439) | 960,277) | 187,640) | 132,619) | 301,959) | 27,135) | 393,652) | 233,288) | 275,809) | 287,455) | 861,853) | (344,587) | 50,352) | 411,473) | 247,246) | ||||||||
| Earnings per share (EPS)2 | 8.36 | 7.99 | 8.55 | 8.26 | 8.89 | 8.24 | 7.72 | 7.40 | -18.02 | -18.24 | -15.74 | -16.69 | 7.69 | 7.78 | 3.15 | 4.15 | 4.59 | 4.42 | 5.64 | 7.83 | 4.99 | 3.89 | 4.46 | 1.67 | 0.00 | 0.00 | 0.00 | ||||||||
| Share price1, 3 | 191.43 | 169.16 | 161.05 | 164.71 | 139.00 | 156.79 | 136.08 | 123.66 | 125.55 | 118.82 | 111.92 | 101.90 | 103.50 | 88.74 | 88.88 | 87.81 | 91.70 | 77.06 | 83.37 | 88.87 | 78.98 | 92.18 | 91.54 | 79.46 | 81.71 | 86.53 | 87.28 | ||||||||
| Valuation Ratio | |||||||||||||||||||||||||||||||||||
| P/E ratio4 | 22.91 | 21.18 | 18.83 | 19.94 | 15.64 | 19.02 | 17.63 | 16.71 | — | — | — | — | 13.46 | 11.41 | 28.18 | 21.14 | 19.98 | 17.42 | 14.79 | 11.36 | 15.81 | 23.70 | 20.54 | 47.54 | — | — | — | ||||||||
| Benchmarks | |||||||||||||||||||||||||||||||||||
| P/E Ratio, Competitors5 | |||||||||||||||||||||||||||||||||||
| Abbott Laboratories | 31.95 | 36.16 | 33.21 | 26.76 | 21.95 | 22.24 | 25.48 | 29.13 | 31.42 | 33.80 | 36.79 | 48.49 | 58.45 | 58.36 | 45.61 | 41.83 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Cigna Group | 17.59 | 12.80 | 11.43 | 13.13 | 14.99 | 15.60 | 15.72 | 13.43 | 8.43 | 8.60 | 10.62 | 8.71 | 14.60 | 12.08 | 13.82 | 13.26 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| CVS Health Corp. | 10.28 | 33.58 | 22.61 | 27.53 | 40.34 | 16.30 | 16.49 | 17.39 | 16.78 | 14.94 | 14.44 | 12.88 | 10.69 | 10.20 | 10.94 | 14.15 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Elevance Health Inc. | 18.14 | 17.03 | 17.46 | 19.20 | 18.75 | 18.07 | 20.46 | 18.13 | 18.65 | 22.10 | 19.99 | 15.87 | 14.35 | 11.97 | 14.80 | 15.96 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Humana Inc. | 19.98 | 17.74 | 20.27 | 22.52 | 25.24 | 19.26 | 18.48 | 18.34 | 22.09 | 22.82 | 15.20 | 14.48 | 13.49 | 15.26 | 19.09 | 18.10 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Intuitive Surgical Inc. | 61.96 | 79.78 | 79.43 | 64.99 | 56.03 | 52.74 | 55.10 | 59.94 | 71.86 | 69.15 | 89.95 | 87.47 | 82.17 | 70.73 | 44.27 | 48.72 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Medtronic PLC | 26.88 | 24.40 | 22.61 | 23.38 | 29.39 | 30.66 | 46.71 | 46.56 | 55.13 | 42.80 | 32.34 | 26.30 | 25.38 | 31.86 | 32.75 | 28.78 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| UnitedHealth Group Inc. | 22.75 | 22.15 | 22.01 | 22.46 | 26.13 | 27.70 | 27.29 | 26.03 | 27.92 | 27.41 | 23.06 | 20.54 | 17.70 | 16.88 | 19.91 | 20.48 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
Based on: 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-Q (reporting date: 2022-12-31), 10-K (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-K (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-K (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-K (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-K (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-K (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-Q (reporting date: 2016-12-31).
1 Data adjusted for splits and stock dividends.
2 Q3 2023 Calculation
EPS
= (Net income (loss) attributable to AmerisourceBergen CorporationQ3 2023
+ Net income (loss) attributable to AmerisourceBergen CorporationQ2 2023
+ Net income (loss) attributable to AmerisourceBergen CorporationQ1 2023
+ Net income (loss) attributable to AmerisourceBergen CorporationQ4 2022)
÷ No. shares of common stock outstanding
= (479,581,000 + 435,402,000 + 479,745,000 + 294,737,000)
÷ 202,174,856 = 8.36
3 Closing price as at the filing date of AmerisourceBergen Corp. Quarterly or Annual Report.
4 Q3 2023 Calculation
P/E ratio = Share price ÷ EPS
= 191.43 ÷ 8.36 = 22.91
5 Click competitor name to see calculations.
| Valuation ratio | Description | The company |
|---|---|---|
| P/E ratio | The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. | AmerisourceBergen Corp. P/E ratio increased from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023. |
Price to Operating Profit (P/OP)
AmerisourceBergen Corp., historical P/OP calculation (quarterly data)
| Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 202,174,856 | 202,466,004 | 202,258,188 | 205,668,628 | 207,258,092 | 209,464,050 | 209,137,429 | 208,133,361 | 207,787,116 | 205,410,717 | 204,706,150 | 204,249,747 | 204,141,795 | 203,402,770 | 205,891,754 | 205,922,186 | 208,325,501 | 210,176,951 | 211,089,893 | 211,933,493 | 216,356,644 | 219,804,069 | 219,669,091 | 218,082,051 | 219,111,565 | 218,356,117 | 217,279,686 | ||||||||
| Selected Financial Data (US$) | |||||||||||||||||||||||||||||||||||
| Operating income (loss) (in thousands) | 670,128) | 560,519) | 633,143) | 454,519) | 487,297) | 780,157) | 644,405) | 561,895) | 620,727) | 624,347) | 547,228) | (6,113,137) | 404,831) | 309,515) | 263,437) | 179,841) | 406,694) | 47,565) | 477,823) | 154,097) | 389,195) | 481,420) | 418,973) | (135,002) | 170,376) | 624,981) | 399,987) | ||||||||
| Operating profit per share2 | 11.47 | 10.55 | 11.64 | 11.51 | 11.94 | 12.45 | 11.72 | 11.31 | -20.79 | -22.09 | -23.70 | -25.14 | 5.67 | 5.70 | 4.36 | 5.40 | 5.21 | 5.08 | 7.12 | 6.81 | 5.34 | 4.26 | 4.91 | 4.86 | 0.00 | 0.00 | 0.00 | ||||||||
| Share price1, 3 | 191.43 | 169.16 | 161.05 | 164.71 | 139.00 | 156.79 | 136.08 | 123.66 | 125.55 | 118.82 | 111.92 | 101.90 | 103.50 | 88.74 | 88.88 | 87.81 | 91.70 | 77.06 | 83.37 | 88.87 | 78.98 | 92.18 | 91.54 | 79.46 | 81.71 | 86.53 | 87.28 | ||||||||
| Valuation Ratio | |||||||||||||||||||||||||||||||||||
| P/OP ratio4 | 16.69 | 16.04 | 13.83 | 14.32 | 11.65 | 12.60 | 11.61 | 10.93 | — | — | — | — | 18.25 | 15.57 | 20.39 | 16.26 | 17.59 | 15.16 | 11.71 | 13.05 | 14.80 | 21.65 | 18.63 | 16.34 | — | — | — | ||||||||
| Benchmarks | |||||||||||||||||||||||||||||||||||
| P/OP Ratio, Competitors5 | |||||||||||||||||||||||||||||||||||
| Abbott Laboratories | 27.48 | 30.47 | 27.70 | 22.18 | 18.35 | 18.63 | 21.33 | 24.45 | 26.84 | 29.01 | 31.39 | 40.69 | 45.82 | 45.19 | 35.87 | 34.03 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Cigna Group | 11.38 | 10.51 | 9.34 | 10.40 | 12.05 | 10.20 | 10.40 | 9.08 | 9.12 | 9.28 | 11.13 | 9.03 | 9.24 | 7.58 | 8.59 | 8.38 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| CVS Health Corp. | 6.32 | 15.41 | 11.67 | 14.75 | 20.01 | 9.97 | 10.06 | 10.43 | 9.43 | 7.87 | 7.61 | 6.65 | 5.89 | 5.98 | 6.19 | 7.83 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Elevance Health Inc. | 14.38 | 13.36 | 13.61 | 15.05 | 15.30 | 14.72 | 17.53 | 15.70 | 15.81 | 19.93 | 15.79 | 12.10 | 10.93 | 9.03 | 11.95 | 13.55 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Humana Inc. | 13.43 | 13.47 | 14.93 | 16.63 | 18.96 | 18.96 | 17.45 | 17.08 | 21.55 | 14.39 | 11.02 | 9.78 | 9.84 | 11.28 | 14.59 | 15.35 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Intuitive Surgical Inc. | 55.63 | 70.08 | 66.95 | 54.49 | 46.65 | 44.54 | 49.98 | 56.11 | 67.95 | 69.51 | 89.18 | 88.37 | 83.88 | 71.30 | 43.68 | 48.89 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Medtronic PLC | 19.53 | 17.99 | 19.55 | 20.48 | 25.40 | 27.20 | 38.83 | 37.44 | 49.88 | 42.55 | 35.86 | 26.29 | 21.01 | 23.52 | 22.21 | 21.26 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| UnitedHealth Group Inc. | 15.63 | 15.33 | 15.41 | 15.89 | 18.75 | 19.96 | 19.69 | 18.77 | 19.63 | 19.05 | 16.12 | 14.12 | 12.35 | 11.85 | 13.80 | 14.40 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
Based on: 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-Q (reporting date: 2022-12-31), 10-K (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-K (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-K (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-K (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-K (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-K (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-Q (reporting date: 2016-12-31).
1 Data adjusted for splits and stock dividends.
2 Q3 2023 Calculation
Operating profit per share
= (Operating income (loss)Q3 2023
+ Operating income (loss)Q2 2023
+ Operating income (loss)Q1 2023
+ Operating income (loss)Q4 2022)
÷ No. shares of common stock outstanding
= (670,128,000 + 560,519,000 + 633,143,000 + 454,519,000)
÷ 202,174,856 = 11.47
3 Closing price as at the filing date of AmerisourceBergen Corp. Quarterly or Annual Report.
4 Q3 2023 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= 191.43 ÷ 11.47 = 16.69
5 Click competitor name to see calculations.
| Valuation ratio | Description | The company |
|---|---|---|
| P/OP ratio | Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. | AmerisourceBergen Corp. P/OP ratio increased from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023. |
Price to Sales (P/S)
AmerisourceBergen Corp., historical P/S calculation (quarterly data)
| Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 202,174,856 | 202,466,004 | 202,258,188 | 205,668,628 | 207,258,092 | 209,464,050 | 209,137,429 | 208,133,361 | 207,787,116 | 205,410,717 | 204,706,150 | 204,249,747 | 204,141,795 | 203,402,770 | 205,891,754 | 205,922,186 | 208,325,501 | 210,176,951 | 211,089,893 | 211,933,493 | 216,356,644 | 219,804,069 | 219,669,091 | 218,082,051 | 219,111,565 | 218,356,117 | 217,279,686 | ||||||||
| Selected Financial Data (US$) | |||||||||||||||||||||||||||||||||||
| Revenue (in thousands) | 66,947,043) | 63,457,205) | 62,846,832) | 61,174,149) | 60,064,601) | 57,719,446) | 59,628,810) | 58,912,421) | 53,405,695) | 49,154,171) | 52,516,556) | 49,244,768) | 45,366,777) | 47,417,639) | 47,864,742) | 45,637,802) | 45,239,265) | 43,319,602) | 45,392,452) | 43,297,136) | 43,142,309) | 41,033,858) | 40,466,332) | 39,120,015) | 38,707,144) | 37,147,402) | 38,169,265) | ||||||||
| Sales per share2 | 1,258.44 | 1,222.64 | 1,195.53 | 1,160.06 | 1,140.25 | 1,096.45 | 1,057.20 | 1,028.13 | 983.32 | 955.56 | 950.37 | 929.71 | 912.54 | 915.23 | 884.26 | 872.12 | 850.82 | 833.35 | 818.92 | 792.42 | 756.91 | 724.86 | 707.61 | 702.23 | 0.00 | 0.00 | 0.00 | ||||||||
| Share price1, 3 | 191.43 | 169.16 | 161.05 | 164.71 | 139.00 | 156.79 | 136.08 | 123.66 | 125.55 | 118.82 | 111.92 | 101.90 | 103.50 | 88.74 | 88.88 | 87.81 | 91.70 | 77.06 | 83.37 | 88.87 | 78.98 | 92.18 | 91.54 | 79.46 | 81.71 | 86.53 | 87.28 | ||||||||
| Valuation Ratio | |||||||||||||||||||||||||||||||||||
| P/S ratio4 | 0.15 | 0.14 | 0.13 | 0.14 | 0.12 | 0.14 | 0.13 | 0.12 | 0.13 | 0.12 | 0.12 | 0.11 | 0.11 | 0.10 | 0.10 | 0.10 | 0.11 | 0.09 | 0.10 | 0.11 | 0.10 | 0.13 | 0.13 | 0.11 | — | — | — | ||||||||
| Benchmarks | |||||||||||||||||||||||||||||||||||
| P/S Ratio, Competitors5 | |||||||||||||||||||||||||||||||||||
| Abbott Laboratories | 4.13 | 4.64 | 4.64 | 4.25 | 3.85 | 4.18 | 4.42 | 4.78 | 5.38 | 5.36 | 5.64 | 6.30 | 6.13 | 5.77 | 5.09 | 4.83 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Cigna Group | 0.49 | 0.46 | 0.42 | 0.49 | 0.55 | 0.48 | 0.48 | 0.42 | 0.42 | 0.42 | 0.55 | 0.46 | 0.50 | 0.41 | 0.45 | 0.44 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| CVS Health Corp. | 0.26 | 0.29 | 0.27 | 0.36 | 0.40 | 0.43 | 0.44 | 0.47 | 0.45 | 0.39 | 0.40 | 0.35 | 0.32 | 0.32 | 0.30 | 0.37 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Elevance Health Inc. | 0.66 | 0.66 | 0.68 | 0.74 | 0.77 | 0.75 | 0.89 | 0.81 | 0.78 | 0.73 | 0.76 | 0.60 | 0.61 | 0.63 | 0.65 | 0.74 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Humana Inc. | 0.59 | 0.61 | 0.66 | 0.68 | 0.78 | 0.68 | 0.65 | 0.65 | 0.73 | 0.71 | 0.73 | 0.64 | 0.76 | 0.76 | 0.74 | 0.76 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Intuitive Surgical Inc. | 13.72 | 17.06 | 16.21 | 13.81 | 12.62 | 12.69 | 15.34 | 17.89 | 22.12 | 21.73 | 23.19 | 21.29 | 20.09 | 18.44 | 13.33 | 15.01 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| Medtronic PLC | 3.55 | 3.42 | 3.79 | 3.72 | 4.54 | 4.54 | 5.74 | 5.57 | 5.71 | 5.43 | 5.11 | 4.36 | 4.34 | 4.82 | 4.72 | 4.36 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
| UnitedHealth Group Inc. | 1.39 | 1.35 | 1.37 | 1.40 | 1.62 | 1.66 | 1.61 | 1.58 | 1.55 | 1.47 | 1.49 | 1.24 | 1.18 | 1.17 | 1.12 | 1.18 | — | — | — | — | — | — | — | — | — | — | — | ||||||||
Based on: 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-Q (reporting date: 2022-12-31), 10-K (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-K (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-K (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-K (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-K (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-K (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-Q (reporting date: 2016-12-31).
1 Data adjusted for splits and stock dividends.
2 Q3 2023 Calculation
Sales per share
= (RevenueQ3 2023
+ RevenueQ2 2023
+ RevenueQ1 2023
+ RevenueQ4 2022)
÷ No. shares of common stock outstanding
= (66,947,043,000 + 63,457,205,000 + 62,846,832,000 + 61,174,149,000)
÷ 202,174,856 = 1,258.44
3 Closing price as at the filing date of AmerisourceBergen Corp. Quarterly or Annual Report.
4 Q3 2023 Calculation
P/S ratio = Share price ÷ Sales per share
= 191.43 ÷ 1,258.44 = 0.15
5 Click competitor name to see calculations.
| Valuation ratio | Description | The company |
|---|---|---|
| P/S ratio | An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. | AmerisourceBergen Corp. P/S ratio increased from Q1 2023 to Q2 2023 and from Q2 2023 to Q3 2023. |
Price to Book Value (P/BV)
AmerisourceBergen Corp., historical P/BV calculation (quarterly data)
| Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | 202,174,856 | 202,466,004 | 202,258,188 | 205,668,628 | 207,258,092 | 209,464,050 | 209,137,429 | 208,133,361 | 207,787,116 | 205,410,717 | 204,706,150 | 204,249,747 | 204,141,795 | 203,402,770 | 205,891,754 | 205,922,186 | 208,325,501 | 210,176,951 | 211,089,893 | 211,933,493 | 216,356,644 | 219,804,069 | 219,669,091 | 218,082,051 | 219,111,565 | 218,356,117 | 217,279,686 | ||||||||
| Selected Financial Data (US$) | |||||||||||||||||||||||||||||||||||
| Total AmerisourceBergen Corporation stockholders’ equity (deficit) (in thousands) | 686,018) | 281,686) | (178,131) | (211,559) | 224,299) | 550,309) | 241,546) | 223,354) | 37,962) | (281,756) | (697,222) | (1,018,924) | 3,857,252) | 3,590,590) | 2,954,626) | 2,878,917) | 2,989,422) | 2,921,215) | 3,048,453) | 2,932,824) | 3,097,821) | 3,187,550) | 2,874,582) | 2,064,461) | 2,553,514) | 2,529,292) | 2,116,557) | ||||||||
| Book value per share (BVPS)2 | 3.39 | 1.39 | -0.88 | -1.03 | 1.08 | 2.63 | 1.15 | 1.07 | 0.18 | -1.37 | -3.41 | -4.99 | 18.89 | 17.65 | 14.35 | 13.98 | 14.35 | 13.90 | 14.44 | 13.84 | 14.32 | 14.50 | 13.09 | 9.47 | 11.65 | 11.58 | 9.74 | ||||||||
| Share price1, 3 | 191.43 | 169.16 | 161.05 | 164.71 | 139.00 | 156.79 | 136.08 | 123.66 | 125.55 | 118.82 | 111.92 | 101.90 | 103.50 | 88.74 | 88.88 | 87.81 | 91.70 | 77.06 | 83.37 | 88.87 | 78.98 | 92.18 | 91.54 | 79.46 | 81.71 | 86.53 | 87.28 | ||||||||
| Valuation Ratio | |||||||||||||||||||||||||||||||||||
| P/BV ratio4 | 56.42 | 121.59 | — | — | 128.44 | 59.68 | 117.82 | 115.23 | 687.20 | — | — | — | 5.48 | 5.03 | 6.19 | 6.28 | 6.39 | 5.54 | 5.77 | 6.42 | 5.52 | 6.36 | 7.00 | 8.39 | 7.01 | 7.47 | 8.96 | ||||||||
| Benchmarks | |||||||||||||||||||||||||||||||||||
| P/BV Ratio, Competitors5 | |||||||||||||||||||||||||||||||||||
| Abbott Laboratories | 4.40 | 5.02 | 5.21 | 5.06 | 4.85 | 5.21 | 5.56 | 5.75 | 6.61 | 6.38 | 6.27 | 6.65 | 6.30 | 5.94 | 5.40 | 4.96 | 4.65 | 4.86 | 4.49 | — | — | — | — | — | — | — | — | ||||||||
| Cigna Group | 2.04 | 1.87 | 1.73 | 1.95 | 2.20 | 1.86 | 1.84 | 1.53 | 1.49 | 1.44 | 1.86 | 1.46 | 1.61 | 1.34 | 1.51 | 1.49 | 1.49 | 1.44 | 1.42 | — | — | — | — | — | — | — | — | ||||||||
| CVS Health Corp. | 1.19 | 1.35 | 1.26 | 1.61 | 1.80 | 1.77 | 1.79 | 1.83 | 1.71 | 1.47 | 1.51 | 1.33 | 1.24 | 1.24 | 1.21 | 1.47 | 1.47 | 1.23 | 1.25 | — | — | — | — | — | — | — | — | ||||||||
| Elevance Health Inc. | 2.87 | 2.86 | 2.90 | 3.19 | 3.24 | 3.08 | 3.55 | 3.07 | 2.88 | 2.67 | 2.78 | 2.19 | 2.10 | 2.06 | 2.23 | 2.42 | 2.13 | 2.40 | 2.15 | — | — | — | — | — | — | — | — | ||||||||
| Humana Inc. | 3.55 | 3.56 | 3.81 | 4.13 | 4.36 | 3.91 | 3.66 | 3.34 | 3.63 | 3.82 | 3.99 | 3.55 | 3.55 | 3.71 | 4.04 | 4.07 | 3.48 | 3.38 | 3.07 | — | — | — | — | — | — | — | — | ||||||||
| Intuitive Surgical Inc. | 7.49 | 9.57 | 9.29 | 7.78 | 6.71 | 6.29 | 7.48 | 8.59 | 10.64 | 10.35 | 10.40 | 9.53 | 9.35 | 9.19 | 7.22 | 8.13 | 8.43 | 8.49 | 8.68 | — | — | — | — | — | — | — | — | ||||||||
| Medtronic PLC | 2.12 | 2.03 | 2.23 | 2.24 | 2.75 | 2.77 | 3.52 | 3.26 | 3.14 | 3.02 | 2.84 | 2.48 | 2.60 | 2.94 | 2.87 | 2.66 | 2.48 | 2.62 | 2.59 | — | — | — | — | — | — | — | — | ||||||||
| UnitedHealth Group Inc. | 5.84 | 5.68 | 5.60 | 5.81 | 6.80 | 6.94 | 6.54 | 6.27 | 6.13 | 5.76 | 5.86 | 4.83 | 4.54 | 4.53 | 4.81 | 4.92 | 4.32 | 4.40 | 4.37 | — | — | — | — | — | — | — | — | ||||||||
Based on: 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-Q (reporting date: 2022-12-31), 10-K (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-Q (reporting date: 2021-12-31), 10-K (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-Q (reporting date: 2020-12-31), 10-K (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-Q (reporting date: 2019-12-31), 10-K (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-Q (reporting date: 2018-12-31), 10-K (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-Q (reporting date: 2017-12-31), 10-K (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-Q (reporting date: 2016-12-31).
1 Data adjusted for splits and stock dividends.
2 Q3 2023 Calculation
BVPS = Total AmerisourceBergen Corporation stockholders’ equity (deficit) ÷ No. shares of common stock outstanding
= 686,018,000 ÷ 202,174,856 = 3.39
3 Closing price as at the filing date of AmerisourceBergen Corp. Quarterly or Annual Report.
4 Q3 2023 Calculation
P/BV ratio = Share price ÷ BVPS
= 191.43 ÷ 3.39 = 56.42
5 Click competitor name to see calculations.